Transgene Valuation Multiples

Transgene Overview

About Transgene

Transgene SA is a biotechnology company that designs and develops targeted immunotherapy products for cancer. Transgene's programs utilize viral vector technology with the goal of indirectly or directly killing infected or cancerous cells. The company's portfolio of products in clinical development includes TG4050, an individualized therapeutic vaccine based on the myvac platform, TG4001, a therapeutic vaccine for HPV positive cancers, as well as BT-001 and TG6050, two oncolytic viruses based on the Invir.IO viral backbone. Transgene has several other programs in clinical and pre-clinical development that are based on its core viral vector technology. Geographically, the majority of its operations are located in France.

Founded

1979

HQ

Employees

165

Website

transgene.fr

Sectors

BiopharmaceuticalsBioTech

Financials (LTM)

Revenue: $9M

EBITDA: ($41M)

EV

$121M

Valuation Multiples

Multiples.vc

Start free trial

Transgene Financials

Transgene reported last 12-month revenue of $9M and negative EBITDA of ($41M).

In the same LTM period, Transgene generated ($41M) in EBITDA losses and had net loss of ($44M).

Transgene P&L

In the most recent fiscal year, Transgene reported revenue of $8M and EBITDA of ($39M).

Transgene expects next 12-month revenue of XXX and NTM EBITDA of XXX

Transgene Stock Performance

Transgene has current market cap of $253M, and enterprise value of $121M.

Transgene's stock price is $0.91.

Transgene Valuation Multiples

Transgene trades at 13.4x EV/Revenue multiple, and (2.9x) EV/EBITDA.

Transgene Financial Valuation Multiples

As of April 18, 2026, Transgene has market cap of $253M and EV of $121M.

Equity research analysts estimate Transgene's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

Transgene has a P/E ratio of (5.7x).

Transgene Margins & Growth Rates

Transgene's revenue in the last 12 month grew by 20%.

Transgene's revenue per employee in the last FY averaged $0.1M, while opex per employee averaged $0.2M for the same period.

Transgene's rule of 40 is 1298% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Transgene's rule of X is 3912% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

Transgene Public Comps

See public comps and valuation multiples for other Biopharmaceuticals comps.

Transgene M&A Activity

Transgene acquired XXX companies to date.

Last acquisition by Transgene was on XXXXXXXX, XXXXX. Transgene acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).

Transgene Investment Activity

Transgene invested in XXX companies to date.

Transgene made its latest investment on XXXXXXXX, XXXXX. Transgene invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).